Corporate Governance
Burjeel Holdings is committed to the highest levels of governance. In 2022 we appointed a Board of Directors with significant international industry and governance experience to help guide us through our next phase of expansion. Our Board of Directors is supported by an Audit Committee, a Nomination and Remuneration Committee and a Clinical and Medical Advisory Committee. The Company is led by a high quality senior management team with a wealth of industry experience.
The Clinical and Medical Advisory Committee provides support and advice to the Board in relation to programs for clinical pathways, the standardisation of care, the identification of best-practice standards, quality and patient safety related KPIs and quality improvement programs. It supports and advises on training, mentoring and development, and provides a connection to, and ongoing exchange of information and ideas with, practitioners in the field and other external contacts.
Across all our brands and businesses, we have implemented effective and transparent governance frameworks, in line with best in class standards and regulatory requirements.
Corporate Governance and Compliance
Leadership Team
Board Committees
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Burjeel Holdings is one of the leading regional private healthcare service providers in the UAE and Oman, operating as an integrated network across primary, secondary, tertiary and quaternary medical care services. It provides a comprehensive healthcare ecosystem to patients across the full socio-economic spectrum through its four key market leading brands, Burjeel, Medeor, LLH and Lifecare.
The Group consists of a fully-funded network of 16 hospitals, 23 medical centres (including polyclinics and specialty medical centres with dental, cosmetic, homecare services, a specialised orthopaedics centre and IVF centres) and 15 pharmacies, as well as seven entities conducting allied services such as central procurement (e.g., GPO), revenue management, centralised diagnostics, central warehousing and patient valet parking services. Leveraging its clinical expertise and strengths in research and development, the Group will also provide medical education and research through its College of Medicine at BMC, beginning in 2023.